Eli Lilly (LLY) Sees Strong Growth Driven by Mounjaro Momentum and GLP-1 Demand, Barclays Remains Bullish

Eli Lilly and Company (NYSE:LLY), featuring a nett income borderline of 34.99% and upside imaginable of 20.64%, secures a spot connected our database of the best highly profitable stocks to bargain according to Wall Street analysts. The institution reported nett income of $20.64 cardinal for the precocious completed fiscal twelvemonth (FY25).

Pixabay/Public Domain

That net spot was besides evident successful the April 30, 2026, update.

Eli Lilly and Company (NYSE:LLY) reported first-quarter 2026 adjusted EPS of $8.55, good supra the $6.66 Wall Street statement tracked by LSEG. The institution besides raised its full-year 2026 adjusted EPS outlook to $35.50-$37.00 from $33.50-$35.00 and lifted gross guidance to $82-$85 cardinal from $80-$83 billion.

Mounjaro remained the standout.

The cause generated $8.7 cardinal successful first-quarter sales, beating expectations by much than $1 billion, with maturation driven chiefly by higher volumes crossed markets. Internationally, absorption said Eli Lilly and Company (NYSE:LLY) overtook Novo Nordisk arsenic the GLP-1 marketplace stock leader. Zepbound added $4.2 cardinal successful sales, besides up of estimates.

In effect to the net release, connected May 5, 2026, Barclays raised its terms people connected Eli Lilly and Company (NYSE:LLY) to $1,400 from $1,350, portion maintaining an “Overweight” rating. Analyst Emily Field pointed to spot crossed Lilly’s tirzepatide franchises, including a 30% bushed for planetary Mounjaro.

Barclays said planetary Mounjaro income are fundamentally each cash-pay successful obesity, pointing to user willingness to wage retired of pocket. The steadfast raised its Mounjaro and Zepbound forecasts, partially offset by a little Foundayo estimation for FY26 of astir $1 billion, compared with the Bloomberg statement of astir $1.4 billion.

That beardown operating backdrop coincided with a large superior markets move.

On May 7, Bloomberg reported that Eli Lilly and Company (NYSE:LLY) sold $9 cardinal successful investment-grade bonds, its largest-ever issuance, to assistance money wide firm purposes and upfront currency information for the Centessa Pharmaceuticals and Kelonia Therapeutics acquisitions.

Eli Lilly and Company (NYSE:LLY) is simply a healthcare institution that develops quality pharmaceutical products crossed cardiometabolic health, oncology, and immunology.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.